Amgen stockholder attending the company’s annual meeting overwhelmingly re-elected four directors to the bio-tech firm’s board. Directors Frank J. Biondi Jr., Jerry D. Choate, Frank C. Herringer and Gilbert S. Omenn received at least 96.5 percent of “for” votes each for reelection. Amgen currently has 10 directors. Stockholders also ratified Ernst & Young as the company’s independent registered public accountant for the year ending Dec. 30, 2007, and approved company-sponsored proposals to amend Amgen’s Restated Certificate of Incorporation and Bylaws to allow the declassification of the board of directors. The two proposals will require the directors to be reelected each year. Stockholders rejected a proposal that would require Amgen to post an animal welfare policy on its Web site and to issue a report to stockholders tracking the adherence to the policy. They also rejected a proposal that would require the company to publish an annual sustainability report disclosing Amgen’s social and environmental practices. Approximately 87 percent of outstanding shares were represented at the meeting.
